Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies (Nasdaq: ADPT) has announced a strategic collaboration with Takeda to utilize its clonoSEQ® Assay for assessing minimal residual disease (MRD) in patients with hematologic malignancies. The partnership aims to enhance the development and commercialization of Takeda's investigational therapies. This multi-year agreement will incorporate existing and future programs, with Adaptive receiving upfront and potential milestone payments. The clonoSEQ Assay is the only FDA-cleared test specifically for MRD in certain blood cancers, offering high accuracy and sensitivity. Both companies emphasize the importance of MRD assessment in predicting patient outcomes and guiding treatment plans.
Adaptive Biotechnologies (Nasdaq: ADPT) announced it will report its financial results for the first quarter of 2023 on May 3, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, which will be accessible via the company’s website. The company focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases, including cancer and autoimmune disorders. Their proprietary platform aims to unlock the full potential of the immune system, enhancing diagnosis and treatment precision. The company emphasizes its commitment to developing individualized immune-driven clinical products.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 43rd Annual Cowen Healthcare Conference in Boston, scheduled for March 6, 2023, at 12:50 p.m. Eastern Time. Management will engage in a fireside chat, with an accessible live and archived webcast available on the company’s website. The company focuses on leveraging the adaptive immune system's genetics to develop clinical products for diagnosing and treating diseases like cancer and autoimmune disorders. Their platform aims to transform disease management through precision and speed.
Adaptive Biotechnologies reported financial results for Q4 and full year 2022, revealing a 20% revenue growth year-over-year, totaling $185.3 million. Q4 revenue reached $55.2 million, a 46% increase from Q4 2021. Key drivers included a 70% surge in MRD revenue and a 54% increase in clonoSEQ test volume. Operating expenses decreased by 5% to $94.4 million, with a net loss of $40.2 million. For 2023, the company aims for revenue between $205 million and $215 million and plans to lower operating expenses. With $498.2 million in cash reserves, Adaptive is positioned for sustainable growth.
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that it will report its financial results for Q4 and the full year of 2022 on February 14, 2023, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, which will be available via webcast on the company's website. Adaptive is focused on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment. The company aims to leverage its proprietary immune medicine platform to address various diseases, including cancer and autoimmune disorders, emphasizing individualized patient care.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 9 at 1:30 PM PT. The presentation will be accessible via a live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on utilizing the adaptive immune system for diagnosing and treating diseases, with products and pipelines aimed at cancer, autoimmune disorders, and infectious diseases. Their proprietary platform enhances drug development and clinical diagnostics.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) showcased the effectiveness of its clonoSEQ Assay at the 64th Annual Meeting of the American Society of Hematology (ASH) on December 10-13, 2022. The assay, the only FDA-cleared test for assessing minimal residual disease (MRD) in lymphoid malignancies, demonstrated high accuracy and sensitivity in measuring MRD in blood cancer patients. Over 30 clonoSEQ-related abstracts were presented, supporting its role in guiding treatment decisions and potentially discontinuing maintenance therapy based on MRD results.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will present over 30 abstracts on its clonoSEQ® Assay at the 64th Annual Meeting of the American Society of Hematology (ASH) from December 10-13, 2022. This FDA-cleared assay measures minimal residual disease (MRD) in various blood cancers, including multiple myeloma and chronic lymphocytic leukemia. The data highlights the assay's role in improving patient care through serial MRD testing, which aids in treatment assessment and relapse detection. Key findings will be shared in 12 oral presentations and 21 posters during the event.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has launched its clonoSEQ Assay for detecting minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This test is notable as it is the first MRD test with Medicare coverage for all therapy lines and timepoints. Now accepting blood samples in Streck® tubes, clonoSEQ offers clinicians a precise, less invasive disease monitoring tool. Robust evidence supports its effectiveness in predicting patient relapses, facilitating better and more timely treatment decisions.
Adaptive Biotechnologies (ADPT) reported third quarter 2022 revenue of $47.8 million, marking a 21% increase year-over-year. clonoSEQ test volume surged by 52% compared to Q3 2021. The Immune Medicine segment revenue rose 18% to $27.9 million. Operating expenses decreased to $93.3 million, down 3% from the prior year. The net loss narrowed to $45.3 million, an improvement from $56.0 million in 2021. Adaptive's 2022 guidance reflects revenue expectations of $185-$190 million and reduced operating expenses below $400 million.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?
What are Adaptive Biotechnologies' future goals?
